Enzo Biochem (Enzo Biochem) Change In Working Capital : $-1.71 Mil (TTM As of Jan. 2024)

View and export this data going back to 1980. Start your Free Trial

What is Enzo Biochem Change In Working Capital?

Enzo Biochem's change in working capital for the quarter that ended in Jan. 2024 was $-5.76 Mil.

Enzo Biochem's change in working capital for the fiscal year that ended in Jul. 2023 was $18.56 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Enzo Biochem Change In Working Capital Historical Data

The historical data trend for Enzo Biochem's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzo Biochem Change In Working Capital Chart

Enzo Biochem Annual Data

Trend

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Change In Working Capital

Get a 7-Day Free Trial

-3.01

7.96

-4.77

-6.84

18.56

Enzo Biochem Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Change In Working Capital	Get a 7-Day Free Trial															5.27	8.92	4.64	-9.51	-5.76

Enzo Biochem Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.71 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Enzo Biochem Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Enzo Biochem's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Enzo Biochem (Enzo Biochem) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Enzo Biochem Inc (NYSE:ENZ) » Definitions » Change In Working Capital

Comparable Companies

PRE DRIO PSNL AWH BIOQ MDXH OCX VNRX BIAF TTOO TMO DHR IQV XSWX:LONN IDXX A MTD ICLR ILMN WAT

Traded in Other Exchanges

EZB:Germany

Address

527 Madison Avenue, New York, NY, USA, 10022

Website

https://www.enzo.com

Enzo Biochem Inc is a bioscience company. The firm manufactures, develops and sell their proprietary solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians internationally. It focuses on delivering and applying its technology to produce products and services to allow its customers to meet their clinical needs. The company has Enzo clinical labs, Enzo life sciences, Enzo therapeutics operating segments. It derives the majority of its revenues from the Clinical lab's segment.

Executives

Steven J Pully	director	9800 RICHMOND AVE, SUITE 700, HOUSTON TX 77042
James G. Wolf	10 percent owner	105, FLYWAY DRIVE, KIAWAH ISLAND SC 29455
Hamid Erfanian	officer: Chief Executive Officer	527 MADISON AVENUE, NEW YORK NY 10022
Patricia Eckert	officer: Interim CFO	C/O ENZO BIOCHEM, INC., 81 EXECUTIVE BLVD, SUITE 3, FARMINGDALE NY 11735
Kara Cannon	officer: Chief Operating Officer	527 MADISON AVE, NEW YORK NY 10022
Bradley Louis Radoff	director	2727 KIRBY DRIVE, UNIT 29L, HOUSTON TX 77098
David Bench	officer: CHIEF FINANCIAL OFFICER	ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK NY 10022
Harbert Discovery Fund, Lp	10 percent owner	HARBERT DISCOVERY FUND GP, LLC, 2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203
Ian B. Walters	director	ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK NY 10022
Mary Tagliaferri	director	455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158
Clemens Peter J Iv	10 percent owner	2383 N. BERRY'S CHAPEL RD., FRANKLIN TN 37069
Rebecca J. Fischer	director	ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK NY 10022
Fabian Blank	10 percent owner, other: See Remarks	ROEMERSTRASSE 6, BAD BERTRICH 2M 56864
Harbert Management Corp	10 percent owner	2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203
Harbert Discovery Co-investment Fund I Gp, Llc	10 percent owner	2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203